title: In vitro and in vivo behaviour of narciclasine released from matrices based on poly (2-hydroxyethyl methacrylate).
abstract: Narciclasine (1,2,3,7-tetrahydroxy-8,9-methylendioxy-1,2,3,4-tetrahydrophena ntridone) is a natural substance with strong antimitotic effects on cells and potential antitumor activity. Its release form a hydrogel matrix was studied with the purpose of avoiding the concentration spikes of the parenteral administration. The matrix prepared by gamma ray polymerization of a mixture of 2-hydroxyethyl methacrylate (85%) and trimethylolpropane trimethacrylate (15%) was found to release narciclasine for several days, according to a diffusion controlled mechanism. In agreement with its antimitotic effect, narciclasine inhibited the growth rate of healthy mice, when the drug-loaded matrix was introduced subcutaneously. Antitumor effect was observed in an experimental model of Erlich ascitic tumor when low amounts of tumor cells were inoculated. No effect was observed at high concentrations of inoculum or towards solid tumors (Sarcoma 180). This behaviour was related to the rapid clearance of narciclasine from the body which prevented the reaching of sufficient therapeutical concentrations. A pharmacokinetic investigation carried out by an original method of assay demonstrated that narciclasine was accumulated in significant amounts in the kidney only and eliminated in urine with a half time of less than 20 min.
authors.affiliation: Dipartimento di Scienze Farmaceutiche (Centro di Studio di Chimica del Farmaco e dei Prodotti Biologicamentea Attivi-C.N.R.), Università di Padova, Italy.
authors.forename: F M
authors.initials: FM
authors.lastname: Veronese
authors.forename: G
authors.initials: G
authors.lastname: Ceriotti
authors.forename: F
authors.initials: F
authors.lastname: Baccichetti
authors.forename: F
authors.initials: F
authors.lastname: Carlassare
authors.forename: F
authors.initials: F
authors.lastname: Moschini
authors.forename: P
authors.initials: P
authors.lastname: Caliceti
authors.forename: O
authors.initials: O
authors.lastname: Schiavon
authors.forename: M
authors.initials: M
authors.lastname: Carenza
authors.forename: S
authors.initials: S
authors.lastname: Lora
mesh_terms: D000470:Alkaloids / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D047151:Amaryllidaceae Alkaloids; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D003692:Delayed-Action Preparations; D005260:Female; D008297:Male; D008689:Methacrylates / Q000737:chemistry; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy; D010617:Phenanthridines; D013050:Spectrometry, Fluorescence; D014018:Tissue Distribution
chemical_list: D000470:Alkaloids; D047151:Amaryllidaceae Alkaloids; D000972:Antineoplastic Agents, Phytogenic; D003692:Delayed-Action Preparations; D008689:Methacrylates; D010617:Phenanthridines; C010753:narciclasine; C005044:hydroxyethyl methacrylate